

September 14, 2021



## Poxel to Host Conference Call for First Half 2021 Financial Results on September 23, 2021

LYON, France--(BUSINESS WIRE)-- [POXEL SA](#) (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders, today announced that it will report and present its financial results for the first half 2021 on Thursday, September 23, 2021.

The management team will host a conference call on September 23, 2021, to present the financial results and provide a corporate update.

- In French, at 12:00 pm ET (New York) /6:00 pm CEST (Paris time).  
To register for the webcast:  
[https://us02web.zoom.us/webinar/register/WN\\_o4kretFCS8uz7iHv0iLmxg](https://us02web.zoom.us/webinar/register/WN_o4kretFCS8uz7iHv0iLmxg)
- In English, at 1:00 pm ET (New York) /7:00 pm CEST (Paris time).  
To register for the webcast:  
[https://us02web.zoom.us/webinar/register/WN\\_Flka34pnTdGsTj\\_fJSvGlw](https://us02web.zoom.us/webinar/register/WN_Flka34pnTdGsTj_fJSvGlw)

A slide presentation to accompany the conference call will be available in the [Investors section](#) of Poxel website.

Participants will be able to submit questions through the webcast chat during the event.

Following the live call, a replay will be available for 90 days on [https://www.poxelpharma.com/en\\_us/investors/company-information/corporate-presentations](https://www.poxelpharma.com/en_us/investors/company-information/corporate-presentations)

### About Poxel SA

Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterated TZD platforms targeting chronic and rare metabolic diseases. For the treatment of NASH, PXL065 (deuterium-stabilized *R*-pioglitazone) is in a streamlined Phase 2 trial (DESTINY1). PXL770, a first-in-class direct AMPK activator, has successfully completed a Phase 2a proof-of-concept trial for the treatment of NASH, which met its objectives. For the

rare inherited metabolic disorder, adrenoleukodystrophy (ALD), the company intends to initiate Phase 2a proof of concept studies with PXL065 and PXL770 in patients with adrenomyeloneuropathy (AMN). TWYMEEG (Imeglimin), Poxel's first-in-class lead product that targets mitochondrial dysfunction, has been approved for the treatment of type 2 diabetes in Japan. With this approval, Poxel is entitled to receive sales-based payments and royalties from Sumitomo Dainippon Pharma. Poxel has a strategic partnership with Sumitomo Dainippon Pharma for Imeglimin in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan.

For more information, please visit: [www.poxelpharma.com](http://www.poxelpharma.com)

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20210914005802/en/>

**Poxel SA**

Catherine David

Investor Relations & Communication Manager

[catherine.david@poxelpharma.com](mailto:catherine.david@poxelpharma.com)

+33 7 64 57 61 78

Aurélie Bozza

Investor Relations & Communication Director

[aurelie.bozza@poxelpharma.com](mailto:aurelie.bozza@poxelpharma.com)

+33 6 99 81 08 36

Elizabeth Woo

Senior Vice President, Investor Relations & Communication

[elizabeth.woo@poxelpharma.com](mailto:elizabeth.woo@poxelpharma.com)

**Investor relations / Media - EU/US**

Trophic Communications

Stephanie May or Valeria Fisher

[poxel@trophic.eu](mailto:poxel@trophic.eu)

+49 171 185 56 82 or +49 175 804 1816

**Investor relations / Media - France**

NewCap

Emmanuel Huynh or Arthur Rouillé

[poxel@newcap.eu](mailto:poxel@newcap.eu)

+33 1 44 71 94 94

Source: Poxel SA